About Vaso (OTCMKTS:VASO)
Vaso Corporation, formerly Vasomedical, Inc., is a medical technology company. The Company is engaged in providing professional sales services for diagnostic imaging products; managed information technology (IT) systems and services, including healthcare software solutions and network connectivity services, and the design, manufacture and sale of proprietary medical devices. The Company's segments include IT segment, which operates through a subsidiary, VasoTechnology, Inc., which focuses on healthcare IT and managed network technology services; Professional sales service segment, which operates through a subsidiary, Vaso Diagnostics, Inc., doing business as VasoHealthcare, which focuses on the sale of healthcare capital equipment for General Electric Healthcare into the health provider middle market, and Equipment segment, which operates through a subsidiary, VasoMedical, Inc., which focuses on the design, manufacture, sale and service of proprietary medical devices.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Trailing P/E Ratio-2.98
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$72.59 million
Price / Sales0.14
Cash Flow$0.02 per share
Price / Cash3.25
Book Value$0.08 per share
Price / Book0.75
Return on Equity-32.56%
Return on Assets-6.47%
Vaso (OTCMKTS:VASO) Frequently Asked Questions
What is Vaso's stock symbol?
Vaso trades on the OTCMKTS under the ticker symbol "VASO."
When will Vaso make its next earnings announcement?
Who are some of Vaso's key competitors?
Some companies that are related to Vaso include Dynatronics (DYNT), Neovasc Inc (US) (NVCN), Valeritas (VLRX), Biocept (BIOC), Orexigen Therapeutics (OREX), Cellectar Biosciences (CLRB), Xenetic Biosciences (XBIO), Soligenix (SNGX), Fibrocell Science (FCSC), Acura Pharmaceuticals (ACUR), Eyegate Pharmaceuticals (EYEG), OpGen (OPGN), Windtree Therapeutics (WINT), Critical Outcome T (COTQF), Neurometrix (NURO), Bioblast Pharma (ORPN), Precipio (PRPO) and Delcath Systems (DCTHD).
Who are Vaso's key executives?
Vaso's management team includes the folowing people:
- Joshua Markowitz Esq., Chairman of the Board (Age 61)
- Jun Ma Ph.D., President, Chief Executive Officer, Director (Age 53)
- David H. Lieberman, Vice Chairman of the Board (Age 72)
- Michael J. Beecher CPA., , Chief Financial Officer, Secretary (Age 72)
- Peter C. Castle, Chief Operating Officer (Age 48)
- Jonathan P. Newton, Vice President - Finance, Controller (Age 56)
- Nelson Randall Hill, Director (Age 70)
- Edgar G. Rios, Director (Age 64)
- Behnam Movaseghi CPA, Independent Director (Age 63)
How do I buy Vaso stock?
Shares of Vaso can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vaso's stock price today?
One share of Vaso stock can currently be purchased for approximately $0.06.
How big of a company is Vaso?
Vaso has a market capitalization of $10.51 million and generates $72.59 million in revenue each year. The company earns $810,000.00 in net income (profit) each year or ($0.02) on an earnings per share basis. Vaso employs 311 workers across the globe.
How can I contact Vaso?
Vaso's mailing address is 137 COMMERCIAL STREET STE. 200, PLAINVIEW NY, 11803. The company can be reached via phone at 516-997-4600 or via email at [email protected]
MarketBeat Community Rating for Vaso (VASO)MarketBeat's community ratings are surveys of what our community members think about Vaso and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vaso (OTCMKTS:VASO) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Vaso (OTCMKTS:VASO) Earnings History and Estimates Chart
Vaso (OTCMKTS VASO) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/29/2018|| || || || || || || || |
|8/14/2017||Q2 2017||($0.01)||$17.85 million||View||N/A|
|5/15/2017||Q1 2017||($0.01)||$16.37 million||View||N/A|
|3/30/2016||Q4 2015||$0.01||$21.38 million||View||N/A|
|11/13/2015||Q3 2015||($0.01)||$17.40 million||View||N/A|
|3/30/2015||Q4 2014||$0.02||$12.36 million||View||N/A|
|5/14/2014||Q1 2014||($0.01)||$7.09 million||View||N/A|
Vaso (OTCMKTS:VASO) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Vaso (OTCMKTS:VASO)
No dividend announcements for this company have been tracked by MarketBeat.com
Vaso (OTCMKTS VASO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.19%
Institutional Ownership Percentage: 0.01%
Vaso (OTCMKTS VASO) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/5/2017||Jun Ma||Insider||Buy||150,000||$0.06||$9,000.00|| |
|11/17/2016||Jun Ma||Insider||Buy||60,000||$0.12||$7,200.00|| |
|11/15/2016||Jun Ma||Insider||Buy||30,000||$0.13||$3,900.00|| |
|8/16/2016||Jun Ma||Insider||Buy||30,000||$0.14||$4,200.00|| |
|5/17/2016||Jun Ma||Insider||Buy||50,000||$0.16||$8,000.00||3,109,841|| |
|11/20/2015||Jun Ma||insider||Buy||40,000||$0.19||$7,600.00||3,109,841|| |
|8/18/2015||Michael Beecher||CFO||Buy||20,000||$0.17||$3,400.00|| |
|8/17/2015||Jun Ma||Insider||Buy||50,000||$0.17||$8,500.00|| |
|6/12/2015||Michael Beecher||CFO||Buy||20,400||$0.18||$3,672.00|| |
|6/9/2015||Jun Ma||Insider||Buy||49,007||$0.17||$8,331.19|| |
Vaso (OTCMKTS VASO) News Headlines
Vaso (OTCMKTS:VASO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Vaso (OTCMKTS:VASO) Income Statement, Balance Sheet and Cash Flow Statement
Vaso (OTCMKTS VASO) Stock Chart for Friday, February, 23, 2018